GlassScriptPhysician profile
Mark S Dacey
NPI 1245433259
$370,480.97
in general payments reported to CMS, 2019-2025
23 companies · $26K in 2025
The $26K reported for 2025 was more than what 97% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $108K · 2020: $23K · 2021: $16K · 2022: $46K · 2023: $31K · 2024: $120K · 2025: $26K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Honoraria: $69K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $59K · Consulting Fee: $24K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $14K · Travel and Lodging: $7,075 · Food and Beverage: $3,840.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Honoraria | $68,640.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $58,912.50 |
| Consulting Fee | $23,560.00 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $14,462.50 |
| Travel and Lodging | $7,075.42 |
| Food and Beverage | $3,839.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $95,859.06 | 2019-2025 | Ozurdex |
| Allergan, INC. | $92,744.61 | 2019-2021 | |
| Alimera Sciences, INC. | $67,091.02 | 2023-2024 | Iluvien, Yutiq |
| Bausch & Lomb Americas INC. | $46,722.56 | 2022-2025 | Xipere, Stellaris, Visudyne |
| Eyepoint US, INC. | $43,753.48 | 2019-2023 | |
| Genentech USA, INC. | $13,831.25 | 2022-2025 | Susvimo, Vabysmo |
| US Retina LLC | $5,943.18 | 2019-2022 | |
| Ani Pharmaceuticals, INC. | $3,612.45 | 2025 | Purified Cortrophin Gel, Yutiq, Iluvien |
| Coherus Oncology, INC. | $196.97 | 2022-2023 | |
| Genentech, INC. | $159.25 | 2021-2024 | |
| Biogen, INC. | $94.84 | 2023-2024 | Byooviz |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $94.77 | 2020 | |
| Heidelberg Engineering, INC. | $75.99 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $57.77 | 2021-2023 | Eylea |
| Novartis Pharmaceuticals Corporation | $45.39 | 2019 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $36.64 | 2019-2020 | |
| Boston Scientific Corporation | $35.82 | 2020-2022 | |
| Harrow Eye, LLC | $28.29 | 2024 | Iheezo |
| Apellis Pharmaceuticals, INC. | $26.13 | 2023 | Syfovre |
| Kala Pharmaceuticals, INC. | $22.28 | 2019 | |
| Alcon Vision LLC | $20.46 | 2022 | |
| Astellas Pharma US INC | $17.44 | 2024 | Izervay |
| Gilead Sciences, INC. | $11.32 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$40,769.23 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Dacey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.